The Morphology Index: Predictive value of malignancy among clinicians at various levels of training

Barnsfather, Kris; Fitzpatrick, Claire; Wilson, Jill; Linn, Cady L.; Brizendine, Edward J.; Schilder, Jeanne M.

doi:10.1016/j.ygyno.2012.06.043

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A morphology index value 5 or greater as indicative of malignancy was associated with the following statistical parameters: sensitivity 98%, specificity 81%, positive predictive value (PPV) 41%, and negative predictive value 99%. 26 The accuracy of this morphology index has been validated both in the United States 27 and internationally. 28,29 In patients with indeterminate tumor morphology, serial morphology index evaluations may be useful.…”

Section: Tumor Morphologymentioning

confidence: 99%

Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women

Nagell

Miller²

2016

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Data from screening trials indicate that a significant percent of asymptomatic women older than 50 years of age will develop ovarian abnormalities that are detectable by ultrasonography. Most of these abnormalities are benign, and many will resolve spontaneously. However, the risk of ovarian cancer, particularly in postmenopausal women, is of concern. The goal is to use a diagnostic and treatment algorithm that will reliably detect ovarian cancer at the earliest possible stage while limiting the number of women undergoing surgery for benign disease. The combination of morphology indexing and serum biomarker analysis can accurately predict the risk of malignancy in most ovarian tumors. Ovarian tumors with cystic or septate morphology are at minimal risk of malignancy and can be followed with serial ultrasonography evaluations, thereby avoiding the morbidity and cost of surgery. Complex or solid ovarian tumors with a high morphology index score, or those with increasing biomarker production, are at a high risk of malignancy, and patients with these tumors should be referred to a gynecologic oncologist for further evaluation and treatment.

show abstract

Section: Tumor Morphologymentioning

confidence: 99%

Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women

Nagell

Miller²

2016

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…There have also been attempts to simplify the IOTA algorithm [17,18], and IOTA has yet to be evaluated in the United States. Other morphology-based indices have been proposed and validated in the U.S. and abroad [19,20,21]. Moreover, much like longitudinal CA125 (ROCA), serial ultrasound offers improved diagnostic results over a single evaluation (Figure 1) [22,23].…”

Section: Presentmentioning

confidence: 99%

A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come

Ueland

2017

Diagnostics

View full text Add to dashboard Cite

The history of biomarkers and ultrasonography dates back over more than 50 years. The present status of biomarkers used in the context of ovarian cancer is addressed. Attention is given to new interpretations of the etiology of ovarian cancer. Cancer antigen 125 (CA125) and multivariate index assays (Ova1, Risk of Ovarian Malignancy Algorithm, Overa) are biomarker-driven considerations that are presented. Integration of biomarkers into ovarian cancer diagnostics and screening are presented in conjunction with ultrasound. Consideration is given to the serial application of both biomarkers and ultrasound, as well as morphology-based indices. Attempts are made to foresee how individualized molecular signatures may be able to both provide an alert of the potential for ovarian cancer and to provide molecular treatments tailored to a personalized genetic signature. In the future, an annual pelvic ultrasound and a comprehensive serum biomarker screening/diagnostic panel may replace the much maligned bimanual examination as part of the annual gynecologic examination. Taken together, it is likely that a new medical specialty for screening and early diagnostics will emerge for physicians and epidemiologists, a field of study that is independent of patient gender, organ, or the subspecialties of today.

show abstract

“…There have also been attempts to simplify the IOTA algorithm [ 13 , 14 ]. Other morphology-based indices have been proposed and validated in the US and elsewhere [ 15 , 16 , 17 ]. Moreover, much similar to longitudinal CA125 (ROCA), serial transvaginal ultrasound (TVUS) offers improved diagnostic results over a single evaluation [ 18 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer

Pilyugin

Ratajska

Stukan

et al. 2021

Genes

View full text Add to dashboard Cite

Background: Ovarian cancer (OC) is the most lethal gynaecological cancer. It is often diagnosed at an advanced stage with poor chances for successful treatment. An accurate blood test for the early detection of OC could reduce the mortality of this disease. Methods: Autoantibody reactivity to 20 epitopes of BARD1 and concentration of cancer antigen 125 (CA125) were assessed in 480 serum samples of OC patients and healthy controls. Autoantibody reactivity and CA125 were also tested for 261 plasma samples of OC with or without mutations in BRCA1/2, BARD1, or other predisposing genes, and healthy controls. Lasso statistic regression was applied to measurements to develop an algorithm for discrimination between OC and controls. Findings and interpretation: Measurement of autoantibody binding to a number of BARD1 epitopes combined with CA125 could distinguish OC from healthy controls with high accuracy. This BARD1-CA125 test was more accurate than measurements of BARD1 autoantibody or CA125 alone for all OC stages and menopausal status. A BARD1-CA125-based test is expected to work equally well for average-risk women and high-risk women with hereditary breast and ovarian cancer syndrome (HBOC). Although these results are promising, further data on well-characterised clinical samples shall be used to confirm the potential of the BARD1-CA125 test for ovarian cancer screening.

show abstract

The Morphology Index: Predictive value of malignancy among clinicians at various levels of training

Cited by 4 publications

References 11 publications

Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women

Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women

A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come

BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer

Contact Info

Product

Resources

About